MedTrace Logo

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

NCT00059462 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2014-12-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.

Conditions

  • HIV Infections

Interventions

DRUG

Interleukin-2 SA

HAART and Bay 50-4798

DRUG

HAART

HAART alone

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2005-03-31
Completion
2005-03-31

Countries

  • United States
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00059462 on ClinicalTrials.gov